Heart failure biomarker and application thereof

A heart failure, gene technology, applied in the field of biomarkers of heart failure), can solve problems such as the difficulty of HFpEF diagnosis

Pending Publication Date: 2020-08-18
承启医学(深圳)科技有限公司
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] However, the results of large-scale clinical randomized controlled trials showed that clinical treatment improved the prognosis of patients with HFrEF, while patients with HFpEF did not benefit, which led researchers to re-examine the morbidity, mortality and mechanisms of HFpEF
In addition, because the ejection fraction is normal in patients with HFpEF, the symptoms and signs of heart failure are often non-specific, so it is difficult for clinicians to diagnose HFpEF

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Heart failure biomarker and application thereof
  • Heart failure biomarker and application thereof
  • Heart failure biomarker and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0114] Example 1: Expression of IL-37a and IL-37b mRNA in canine heart failure animal models

[0115] 1. Construction of a canine paced heart failure model

[0116] The canine heart failure model is constructed by tachycardia induction, that is, implanting pacing electrodes in the left or right ventricle of the model animal dog to make the heart rate supernormal, usually three times the baseline value, usually for 3 to 5 weeks.

[0117] Tachycardia Induced Construction of Canine Heart Failure Model Reference: Kiyotake Ishikawa (ed.), Experimental Models of Cardiovascular Diseases: Methods and Protocols, Methods in Molecular Biology, vol. 1816, Chapter 24, Canine Model of Pacing-Induced Heart Failure, Springer Science+Business Media, LLC, part of Springer Nature 2018.

[0118] 2. Blood collection before modeling

[0119] Blood was collected from the lateral small saphenous vein of the hind limb: the lateral small saphenous vein of the hind limb was subcutaneously located on th...

Embodiment 2

[0132] Example 2: Expression of IL-37a and IL-37b mRNA in each group of clinical samples Ctrl group, HFrEF group, HFmrEF group and HFpEF group

[0133] 1. Blood samples were collected from the normal control group (Ctrl group), HFrEF (HFrEF group), HFmrEF (HFmrEF group) and HFpEF (HFpEF group) patients from healthy subjects.

[0134] Entry requirements: The diagnostic criteria for heart failure refer to the 2014 Chinese Heart Failure Guidelines: with symptoms and signs of heart failure; NT-proBNP>300pg / ml.

[0135] Exclusion criteria: patients younger than 18 years old; LVEF<50% and various congenital heart disease, valvular heart disease, cardiomyopathy, pericardial disease, acute myocardial infarction, acute myocarditis, primary pulmonary hypertension, persistent atrial fibrillation, hyperthyroidism , hypothyroidism, tumors, etc.; patients with incomplete main clinical data (such as lack of LVEF, NT-proBNP, etc.). For patients with repeat hospitalization within one year, th...

Embodiment 3

[0149] Example 3: ELISA detection of IL-37a and IL-37b protein expression in clinical samples Ctrl group, HFrEF group, HFmrEF group and HFpEF group

[0150] 1. ELISA experiments were carried out based on the clinical plasma samples collected in Example 2.

[0151] 2. Plasma total protein extraction and determination

[0152] (1) Take 50μL of plasma and add 50μL of lysis solution (100×PMSF, 100×cocktail and phosphatase inhibitor have been added in advance), mix well, lyse on ice for 15min, centrifuge at 13000g for 10min at 4°C, and take the supernatant.

[0153] (2) Determination of protein concentration by BCA method.

[0154] (3) After calculating the sample volume according to the protein concentration determined by the BCA method, add 5×SDS-loading buffer and boil at 100°C for 10min.

[0155] 3. ELISA experiment

[0156] ELISA experiments were carried out on IL-37a and IL-37b proteins according to the instructions of the ELISA kits, and the data were sorted and the actua...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a heart failure biomarker and application thereof. The biomarker is IL-37, particularly IL-37a and IL-37b. The inventor finds that IL-37a and IL-37b are highly expressed in heart failure patients from plasma mRNA and plasma protein levels, and can distinguish heart failure patients and healthy people. For three types of heart failure: HFrEF, HFmrEF and HFpEF, research and comparison are carried out on IL-37a and IL-37b from the plasma mRNA and plasma protein levels, and it is found that the IL-37a / IL-37b ratio can be used as an early screening and early diagnosis markerfor identifying the HFpEF. Theoretical basis and guiding significance can be provided for early screening, early diagnosis and the like of heart failure (especially HFpEF), and the survival rate of patients can be increased.

Description

technical field [0001] The present invention relates to the field of biomedical technology, in particular to a biomarker for heart failure (especially heart failure with preserved ejection fraction (HFpEF)), such as IL-37a and IL-37b, and Its use, in particular the IL-37a / IL-37b ratio, in the diagnosis and prognosis of heart failure, especially HFpEF. Background technique [0002] Heart failure (HF) is referred to as heart failure, which means that due to the dysfunction of the systolic and / or diastolic function of the heart, the venous return blood cannot be fully discharged from the heart, resulting in blood stasis in the venous system and insufficient blood perfusion in the arterial system. resulting in cardiac circulatory disorder. According to the ejection fraction (EF), heart failure can be divided into: [0003] (1) HF with reduced ejection fraction (HFrEF), where EF is less than 40%; [0004] (2) HF with mid-range ejection fraction (HFmrEF), where EF is between 40...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12Q1/6883C12N15/11G01N33/68A61K45/00A61P9/04
CPCC12Q1/6883G01N33/6869G01N33/6893A61K45/00A61P9/04C12Q2600/118C12Q2600/158C12Q2600/166G01N2333/54G01N2800/325G01N2800/52
Inventor 董鸣吴婷婷杨子仪
Owner 承启医学(深圳)科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap